Valuation: Lakefront Biotherapeutics NV

Market Cap 1.67B 1.95B 1.56B 1.43B 2.7B 187B 2.74B 18.45B 7.22B 93.56B 7.33B 7.17B 309B P/E 2026 *
-13.5x
P/E 2027 * -6.81x
Enterprise Value -756M -882M -706M -648M -1.22B -84.27B -1.24B -8.33B -3.26B -42.26B -3.31B -3.24B -140B EV / Sales 2026 *
-7.97x
EV / Sales 2027 * -6.31x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Lakefront Biotherapeutics NV

1 day+7.05%
1 week+4.34%
Current month+6.87%
1 month-1.92%
3 months+10.77%
6 months-11.64%
Current year-8.93%
1 week 23.64
Extreme 23.64
25.72
1 month 22.32
Extreme 22.32
25.94
Current year 22.32
Extreme 22.32
30.72
1 year 22.32
Extreme 22.32
32.74
3 years 20
Extreme 20
39
5 years 20
Extreme 20
66.28
10 years 20
Extreme 20
252.9
Manager TitleAgeSince
Chief Executive Officer 53 11/05/2025
Director of Finance/CFO 41 06/07/2025
Chief Operating Officer - 31/05/2026
Director TitleAgeSince
Director/Board Member 63 21/10/2019
Director/Board Member 49 06/10/2024
Director/Board Member 53 11/05/2025
Date Insider Type Main position Quantity % Market Cap.
28/01/26 Buy

Director

137 0.0002%
28/01/26 Buy

Director

375 0.0006%
28/01/26 Free

General Counsel

235,000 0.3566%
Change 5-day change 1-year change 3-year change Capi.($)
+7.05%+4.34%-7.88%-28.79% 1.81B
+2.37%+2.30%+3.39%+22.74% 48.63B
-0.62%+4.58%+487.47%+624.71% 46.3B
+2.09%+4.96%+20.59%+95.21% 41.97B
+3.85%+3.13%+29.60%+16.50% 39.51B
-0.72%-3.91%+17.87%+47.98% 31.75B
+3.04%+1.89%+31.62%+143.62% 16.48B
+4.33%+1.63% - - 16.34B
+1.44%+1.52%+4.22%+31.00% 14B
+3.87%+1.98%+82.99%+45.80% 13.33B
Average +2.67%+1.38%+74.43%+110.97% 27.01B
Weighted average by Cap. +1.88%+0.99%+106.42%+155.88%

Financials

2026 *2027 *
Net sales 94.87M 111M 88.58M 81.27M 153M 10.57B 155M 1.05B 409M 5.3B 415M 406M 17.53B 93.29M 109M 87.11M 79.92M 150M 10.4B 153M 1.03B 403M 5.21B 408M 399M 17.24B
Net income -40.7M -47.44M -38M -34.86M -65.56M -4.53B -66.64M -448M -176M -2.27B -178M -174M -7.52B -213M -248M -199M -182M -343M -23.7B -348M -2.34B -918M -11.89B -931M -911M -39.3B
Net Debt -2.43B -2.83B -2.27B -2.08B -3.92B -271B -3.98B -26.78B -10.49B -136B -10.64B -10.41B -449B -2.26B -2.64B -2.11B -1.94B -3.65B -252B -3.71B -24.94B -9.77B -126B -9.91B -9.69B -418B
Logo Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
452
Date Price Change Volume
19/08/26 €25.50 +7.05% 176,325
18/08/26 €23.82 -1.41% 81,616
17/08/26 €24.16 +1.09% 63,490
14/08/26 €23.90 -1.65% 68,150
13/08/26 €24.30 -0.57% 93,285
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
9
Last Close Price
25.50EUR
Average target price
30.28EUR
Spread / Average Target
+18.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LKFT Stock